J. Sloan-Lancaster

发表

Determination of the mechanism of action of anti-FasL antibody by epitope mapping and homology modeling.

Lihua Huang, V. Obungu, V. Gelfanova, 2009, Biochemistry.

LAT The ZAP-70 Tyrosine Kinase Substrate that Links T Cell Receptor to Cellular Activation

L. Samelson, J. Sloan-Lancaster, Lawrence E Samelson, 1998, Cell.

Induction of T-cell anergy by altered T-cell-receptor ligand on live antigen-presenting cells

P. Allen, B. Evavold, J. Sloan-Lancaster, 1993, Nature.

Evaluation of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy After Single and Multiple Dosings of LY3016859 in Healthy Subjects and Patients With Diabetic Nephropathy

J. Tumlin, J. Sloan-Lancaster, M. Deeg, 2018, Clinical pharmacology in drug development.

Double-Blind , Randomized Study Evaluating the Glycemic and Anti-in fl ammatory Effects of Subcutaneous LY 2189102 , a Neutralizing IL-1 b Antibody , in PatientsWith Type 2 Diabetes

E. Abu-Raddad, A. Gaetano, W. Landschulz, 2013 .

Tabalumab in rheumatoid arthritis patients with an inadequate response to methotrexate and naive to biologic therapy: a phase II, randomized, placebo-controlled trial.

M. Genovese, J. Sloan-Lancaster, L. Georgescu, 2013, Arthritis and rheumatism.

LY3045697: Results from two randomized clinical trials of a novel inhibitor of aldosterone synthase

J. Sloan-Lancaster, Jeffrey W. Miller, E. Raddad, 2017, Journal of the renin-angiotensin-aldosterone system : JRAAS.

Separation of T helper 1 clone cytolysis from proliferation and lymphokine production using analog peptides.

P. Allen, B. Evavold, J. Sloan-Lancaster, 1993, Journal of immunology.

Population Pharmacokinetic Modeling of LY2189102 after Multiple Intravenous and Subcutaneous Administrations

E. Ludwig, J. Sloan-Lancaster, J. Fiedler-Kelly, 2014, The AAPS Journal.

Regulation of ZAP-70 Intracellular Localization: Visualization with the Green Fluorescent Protein

J. Lippincott-Schwartz, R. Abraham, L. Samelson, 1997, The Journal of experimental medicine.

Pharmacometric Analyses to Support Early Development Decisions for LY2878735: A Novel Serotonin Norepinephrine Reuptake Inhibitor

J. Sloan-Lancaster, S. V. Van Wart, C. Rubino, 2013, CPT: pharmacometrics & systems pharmacology.

Signalling events in the anergy induction of T helper 1 cells.

P. Allen, J. Sloan-Lancaster, 1995, Ciba Foundation symposium.

Selective loss of the calcium ion signaling pathway in T cells maturing toward a T helper 2 phenotype.

P. Allen, T. Steinberg, J. Sloan-Lancaster, 1997, Journal of immunology.

Antagonism of superantigen-stimulated helper T-cell clones and hybridomas by altered peptide ligand.

P. Allen, B. Evavold, J. Sloan-Lancaster, 1994, Proceedings of the National Academy of Sciences of the United States of America.

Selective activation of the calcium signaling pathway by altered peptide ligands

P. Allen, T. Steinberg, J. Sloan-Lancaster, 1996, The Journal of experimental medicine.

Altered peptide ligand-induced partial T cell activation: molecular mechanisms and role in T cell biology.

P. Allen, J. Sloan-Lancaster, P M Allen, 1996, Annual review of immunology.

Specific T cell recognition of minimally homologous peptides: evidence for multiple endogenous ligands.

J. Rothbard, P. Allen, B. Evavold, 1995, Immunity.

Partial T cell signaling: Altered phospho-ζ and lack of zap70 recruitment in APL-induced T cell anergy

Paul M. Allen, J. Rothbard, P. Allen, 1994, Cell.

Tickling the TCR: selective T-cell functions stimulated by altered peptide ligands.

P. Allen, B. Evavold, J. Sloan-Lancaster, 1993, Immunology today.

Proximal Events in T-Cell Activation

L. Samelson, J. Sloan-Lancaster, 2000 .

ZAP-70 Association with T Cell Receptor ζ (TCRζ): Fluorescence Imaging of Dynamic Changes upon Cellular Stimulation

J. Lippincott-Schwartz, J. Ellenberg, T. Yamazaki, 1998, The Journal of cell biology.

Th2 cell clonal anergy as a consequence of partial activation

P. Allen, B. Evavold, J. Sloan-Lancaster, 1994, The Journal of experimental medicine.

Significance of T-cell stimulation by altered peptide ligands in T cell biology.

P. Allen, J. Sloan-Lancaster, Paul M. Allen, 1995, Current opinion in immunology.

Differential Mechanisms of Plasminogen Activator Inhibitor-1 Gene Activation by Transforming Growth Factor-β and Tumor Necrosis Factor-α in Endothelial Cells

J. Tseng-Crank, Yan Chen, J. Sloan-Lancaster, 2001, Thrombosis and Haemostasis.

LY2439821, a humanized anti-interleukin-17 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: A phase I randomized, double-blind, placebo-controlled, proof-of-concept study.

M. Genovese, F. E. Van den Bosch, J. Sloan-Lancaster, 2010, Arthritis and rheumatism.

Double-Blind, Randomized Study Evaluating the Glycemic and Anti-inflammatory Effects of Subcutaneous LY2189102, a Neutralizing IL-1β Antibody, in Patients With Type 2 Diabetes

Andrea De Gaetano, A. De Gaetano, E. Abu-Raddad, 2013, Diabetes Care.

Population Pharmacokinetic Modeling of LY2189102 after Multiple Intravenous and Subcutaneous Administrations

E. Ludwig, J. Sloan-Lancaster, J. Fiedler-Kelly, 2014, The AAPS Journal.

Targeting Calcium Release–activated Calcium Channel Is Not Sufficient to Prevent Rejection in Nonhuman Primate Kidney Transplantation

S. Knechtle, J. Kwun, M. Manook, 2020, Transplantation.

Differential mechanisms of plasminogen activator inhibitor-1 gene activation by transforming growth factor-beta and tumor necrosis factor-alpha in endothelial cells.

J. Tseng-Crank, J. Sloan-Lancaster, M. Richardson, 2001, Thrombosis and haemostasis.